申请人:Sugen, Inc.
公开号:US20040024010A1
公开(公告)日:2004-02-05
The present invention relates to novel 3-methylidenyl-2-indolinone compounds and physiologically acceptable salts and prodrugs thereof which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.
本发明涉及新型的3-甲基亚烯基-2-吲哚酮化合物及其生理上可接受的盐和前药,这些化合物可调节蛋白激酶的活性,因此预计在预防和治疗蛋白激酶相关的细胞疾病,如癌症方面具有用途。